Enthera
Founded Year
2016Stage
Series A - II | AliveTotal Raised
$47.1MLast Raised
$9.58M | 3 yrs agoAbout Enthera
Enthera is a company focused on the development of first-in-class therapeutics in the healthcare and biotechnology industry. The company's main offerings include biologics designed to treat several underserved autoimmune conditions, with a therapeutic approach that aims to preserve and re-establish organ cell function. It was founded in 2016 and is based in Milan, Italy.
Loading...
Loading...
Enthera Patents
Enthera has filed 4 patents.
The 3 most popular patent topics include:
- immunology
- designer drugs
- growth factors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/2/2019 | Transcription factors, Human proteins, Immunology, Growth factors, Peptides | Application |
Application Date | 10/2/2019 |
|---|---|
Grant Date | |
Title | |
Related Topics | Transcription factors, Human proteins, Immunology, Growth factors, Peptides |
Status | Application |
Latest Enthera News
Mar 7, 2023
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001. Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Elevated levels of IGFBP3 bind to the TMEM219 receptor, causing apopt
Enthera Frequently Asked Questions (FAQ)
When was Enthera founded?
Enthera was founded in 2016.
Where is Enthera's headquarters?
Enthera's headquarters is located at Via Gioberti 8, Milan.
What is Enthera's latest funding round?
Enthera's latest funding round is Series A - II.
How much did Enthera raise?
Enthera raised a total of $47.1M.
Who are the investors of Enthera?
Investors of Enthera include Roche Venture Fund, Sofinnova Partners, JDRF T1D Fund, AbbVie Biotech Ventures, Banca Profilo and 5 more.
Loading...
Loading...